IQ EQ FUND MANAGEMENT IRELAND Ltd Has $1.40 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,390 shares of the company’s stock after acquiring an additional 84 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IDEXX Laboratories were worth $1,402,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Insight Wealth Strategies LLC grew its position in shares of IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after purchasing an additional 7,041 shares in the last quarter. Geode Capital Management LLC grew its position in IDEXX Laboratories by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock worth $1,138,732,000 after buying an additional 40,349 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in IDEXX Laboratories during the 3rd quarter worth $1,263,000. Sax Wealth Advisors LLC raised its holdings in IDEXX Laboratories by 76.3% in the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock valued at $590,000 after acquiring an additional 617 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its position in shares of IDEXX Laboratories by 11.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after acquiring an additional 800 shares during the period. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IDXX. Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Up 1.2 %

Shares of IDXX stock opened at $422.54 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The stock’s fifty day simple moving average is $437.13 and its 200 day simple moving average is $443.72. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $34.25 billion, a P/E ratio of 39.60, a P/E/G ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.